Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 18/20 | 0.54 |
| ▸ | CDK12 | Q9NYV4 | 18/20 | 0.54 |
| ▸ | CDK2 | P24941 | 16/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 15/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 15/20 | 0.54 |
| ▸ | CDK9 | P50750 | 15/20 | 0.54 |
| ▸ | CDK7 | P50613 | 10/20 | 0.48 |
| ▸ | CCNH | P51946 | 8/20 | 0.44 |
| ▸ | MNAT1 | P51948 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17688422 | 0.93 | CCNK (0.54) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL19600367 | 0.91 | CDK7 (0.49) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL19605656 | 0.91 | CCNK (0.48) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL17688431 | 0.84 | CCNT1 (0.58) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL19605708 | 0.83 | CCNK (0.47) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL19600385 | 0.83 | CDK7 (0.45) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL19600378 | 0.83 | CDK7 (0.47) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL19600369 | 0.81 | CDK7 (0.54) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL17688366 | 0.80 | CCNK (0.45) | CCNKCDK12CDK2CCNE1CCNT1 | |
| SCHEMBL17696323 | 0.80 | CCNK (0.69) | CCNKCDK12CDK2CCNE1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200123499-A1 | METHOD FOR EFFICIENT GENERATION OF NEURONS FROM NON-NEURONAL CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-04-23 | — | — | US | disclosed |
| US-20190337940-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-11-07 | — | — | US | disclosed |
| US-20190337940-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-11-07 | — | — | US | disclosed |
| US-10308648-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308648-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-11-16 | — | — | US | disclosed |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-11-16 | — | — | US | disclosed |
| WO-2016058544-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| WO-2016058544-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337940-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CCNK 6/4885CDK12 28/4885CDK2 8/4885 |
| US-10308648-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CCNK 6/4885CDK12 28/4885CDK2 8/4885 |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CCNK 6/4885CDK12 28/4885CDK2 8/4885 |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CCNK 6/4885CDK12 28/4885CDK2 8/4885 |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CCNK 6/4885CDK12 28/4885CDK2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.